SK16082000A3 - Ľudský bmp-7 promótor a spôsob výskumu substancií ovplyvňujúcich kosť pri použití tohto promótora - Google Patents
Ľudský bmp-7 promótor a spôsob výskumu substancií ovplyvňujúcich kosť pri použití tohto promótora Download PDFInfo
- Publication number
- SK16082000A3 SK16082000A3 SK1608-2000A SK16082000A SK16082000A3 SK 16082000 A3 SK16082000 A3 SK 16082000A3 SK 16082000 A SK16082000 A SK 16082000A SK 16082000 A3 SK16082000 A3 SK 16082000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- bone
- vector
- dna
- human
- human bmp
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000000126 substance Substances 0.000 title claims description 31
- 210000000988 bone and bone Anatomy 0.000 title abstract description 17
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 title 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims abstract description 27
- 239000013598 vector Substances 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 16
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 15
- 208000017169 kidney disease Diseases 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 239000013604 expression vector Substances 0.000 claims description 21
- 238000003259 recombinant expression Methods 0.000 claims description 21
- 108060001084 Luciferase Proteins 0.000 claims description 9
- 239000005089 Luciferase Substances 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000011164 ossification Effects 0.000 claims description 4
- 230000003169 placental effect Effects 0.000 claims description 4
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 102000046107 human BMP7 Human genes 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 11
- 150000003384 small molecules Chemical class 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 210000000845 cartilage Anatomy 0.000 abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 abstract description 7
- 210000004102 animal cell Anatomy 0.000 abstract description 5
- 230000001002 morphogenetic effect Effects 0.000 abstract description 5
- 238000011144 upstream manufacturing Methods 0.000 abstract description 5
- 208000020084 Bone disease Diseases 0.000 abstract description 4
- 208000015100 cartilage disease Diseases 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 22
- 101100165559 Homo sapiens BMP7 gene Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 6
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 102100035379 Growth/differentiation factor 5 Human genes 0.000 description 4
- 101710204282 Growth/differentiation factor 5 Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000046148 human BMP4 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 206010008723 Chondrodystrophy Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000762365 Mus musculus Bone morphogenetic protein 2 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000008919 achondroplasia Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000007355 cartilage morphogenesis Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- -1 small molecule organic compounds Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (3)
1/3
Obr. 1 • ···· ·· · ·· • · · · · ·· · · · • · · · · · · • · ··· ··· ··· · ·· ··· ·· ···
01-3053-00-Ma • ···· ·· · ·· ·* · · · ·· · · · ··· · ·· ··· ·· ···
(1) trávenie ľudskej placentárnej genómovej DNA reštrikčným enzýmom HindlII;
1. DNA, ktorej nukleotidová sekvencia je tvorená bázami č. 1 až 10877 v SEQ ID NO: 1 Zoznamu sekvencií, ktorá kóduje promotorový región ľudského kostného morfogenetického proteínu 7, alebo jej fragment.
2/3
Sad Mlul
ΗίηάΙΠ
Smal Xhol
Bglll
Bglll
Obr. 2
(2) izoláciu elektroforézou na agarózovom géli;
(3) klonovanie izolovaného DNA fragmentu tráveného HindlII do lambda fágového vektoru ÁDASH II spracovaného rovnakým enzýmom;
(4) zabalenie uvedeného vektoru do fágu;
(5) vytvorenie knižnice genómovej DNA pomocou infekcie Escherichia coli fágom;
(6) vyšetrovanie PCR; a (7) subklonovanie do plazmidového vektoru.
3. Rekombinantný expresný vektor, vyznačujúci sa t ý m, že obsahuje v reportérovom géne integrovanú úplnú alebo čiastočnú DNA uvedenú v SEQ ID NO: 1 Zoznamu sekvencií.
4. Spôsob pre výskum substancií ovplyvňujúcich kosť, vyznačujúci sa tým, že využíva rekombinantný expresný vektor podľa nároku 3.
5. Spôsob pre výskum substancií ovplyvňujúcich kosť podľa nároku 4,vyznačujúci sa tým, že substancia ovplyvňujúca kost je substancia indukujúca osteogenézu.
6. Spôsob pre výskum substancií ovplyvňujúcich kost podľa nároku 4,vyznačujúci sa tým, že substancia ovplyvňujúca kosť je substancia inhibujúca osteogenézu.
7. Spôsob pre výskum substancií účinných pri liečbe ochorení obličiek, vyznačujúci sa tým, že využíva rekombinantný expresný vektor podľa nároku 3.
2. Spôsob prípravy DNA uvedenej v SEQ ID NO: 1 Zoznamu sekvencií, vyznačujúci sa tým, že obsahuje nasledujúce kroky:
3/3
Relatívna aktivita luciferázy (RLU)
HOS MG63
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10120174A JPH11313675A (ja) | 1998-04-30 | 1998-04-30 | ヒトｂｍｐ−７プロモーターおよびこれを用いた骨関連物質の探索法 |
| PCT/IB1999/000733 WO1999057293A1 (en) | 1998-04-30 | 1999-04-22 | Human bmp-7 promoter and method for exploring bone-related substance by using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK16082000A3 true SK16082000A3 (sk) | 2001-05-10 |
Family
ID=14779761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1608-2000A SK16082000A3 (sk) | 1998-04-30 | 1999-04-22 | Ľudský bmp-7 promótor a spôsob výskumu substancií ovplyvňujúcich kosť pri použití tohto promótora |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6534268B1 (sk) |
| EP (1) | EP1076713A1 (sk) |
| JP (1) | JPH11313675A (sk) |
| KR (1) | KR20010071193A (sk) |
| CN (1) | CN1170941C (sk) |
| AP (1) | AP1329A (sk) |
| AU (1) | AU769124B2 (sk) |
| BG (1) | BG64780B1 (sk) |
| BR (1) | BR9910585A (sk) |
| CA (1) | CA2326957A1 (sk) |
| EA (1) | EA004509B1 (sk) |
| EE (1) | EE200000627A (sk) |
| GE (1) | GEP20033056B (sk) |
| HR (1) | HRP20000736A2 (sk) |
| HU (1) | HUP0102329A3 (sk) |
| ID (1) | ID26704A (sk) |
| IL (1) | IL139100A0 (sk) |
| NO (1) | NO20005433D0 (sk) |
| NZ (1) | NZ507625A (sk) |
| PL (1) | PL343817A1 (sk) |
| SK (1) | SK16082000A3 (sk) |
| TR (1) | TR200003182T2 (sk) |
| UA (1) | UA72212C2 (sk) |
| WO (1) | WO1999057293A1 (sk) |
| YU (1) | YU64900A (sk) |
| ZA (1) | ZA200006080B (sk) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006516548A (ja) | 2002-12-30 | 2006-07-06 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 迅速ゲル化ポリマー組成物からの薬物送達法 |
| US20070015701A1 (en) * | 2005-06-01 | 2007-01-18 | Samuel Zalipsky | Macromolecular conjugates of bone morphogenetic protein-7 |
| DK2078073T3 (da) * | 2006-10-12 | 2013-10-28 | Ethicon Inc | Nyreafledte celler og fremgangsmåder til anvendelse deraf til vævsreparation og -regenerering |
| CA2681317C (en) * | 2008-05-16 | 2013-04-02 | Industry Foundation Of Chonnam National University | A synthetic peptide containing bone forming peptide 1(bfp 1) for stimulating osteoblast differentiation, and pharmaceutical composition comprising the synthetic peptide |
| CA2799641C (en) | 2010-06-09 | 2016-08-30 | Semprus Biosciences Corp. | Articles having non-fouling surfaces and processes for preparing the same including applying a primer coat |
| CA2799786A1 (en) | 2010-06-09 | 2011-12-15 | Semprus Biosciences Corp. | Non-fouling, anti-microbial, anti-thrombogenic graft compositions |
| KR20130110143A (ko) | 2010-06-09 | 2013-10-08 | 셈프러스 바이오사이언시스 코퍼레이션 | 방오성, 항균성, 항혈전성 그라프트-프롬 조성물 |
| WO2012024489A2 (en) | 2010-08-18 | 2012-02-23 | Emory University | Compounds and compositions for ossification and methods related thereto |
| WO2012116137A2 (en) | 2011-02-24 | 2012-08-30 | Emory University | Jab1 blocking compositions for ossification and methods related thereto |
| EP2678050B1 (en) | 2011-02-24 | 2020-10-14 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| JP2015507761A (ja) | 2011-12-14 | 2015-03-12 | センプラス・バイオサイエンシーズ・コーポレイションＳｅｍｐｒｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐ． | コンタクトレンズ改質のためのレドックス法 |
| EP2791211A4 (en) | 2011-12-14 | 2015-08-05 | Semprus Biosciences Corp | MULTI-STAGE UV PROCESS FOR CREATING CONTACT LENSES WITH MODIFIED SURFACE |
| US9006359B2 (en) | 2011-12-14 | 2015-04-14 | Semprus Biosciences Corporation | Imbibing process for contact lens surface modification |
| MX2014007211A (es) | 2011-12-14 | 2015-04-14 | Semprus Biosciences Corp | Lente de contacto de hidrogel de silicona modificada usando oxidantes de lantanido o de metal de transicion. |
| MX2014007202A (es) | 2011-12-14 | 2015-03-09 | Semprus Biosciences Corp | Lentes de contacto modificadas en la superficie. |
| WO2019005563A1 (en) * | 2017-06-27 | 2019-01-03 | St. Jude Children's Research Hospital | METHODS ASSOCIATED WITH THE ACTIVATION OF THE SIGNALING PATHWAY OF BONE MORPHOGENETIC PROTEINS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| DE69031939T2 (de) | 1989-03-28 | 1998-09-10 | Genetics Institute, Inc., Cambridge, Mass. | Osteoinduktive zusammensetzungen |
| US5650276A (en) * | 1991-03-11 | 1997-07-22 | Creative Biomolecules, Inc. | Morphogenic protein screening method |
| WO1993003382A2 (en) * | 1991-08-01 | 1993-02-18 | Pharmaceutical Discovery Corporation | Characterization of specific drug receptors with fluorescent ligands |
| CA2191583C (en) * | 1994-06-07 | 2007-03-27 | Engin Ozkaynak | Methods and compositions for modulating morphogenic protein expression |
| US6083690A (en) * | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
| EP0937145A1 (en) * | 1996-11-22 | 1999-08-25 | Akzo Nobel N.V. | Bmp-4 promoter and use thereof in screening of therapeutic agents for the prevention and/or treatment of osteoporosis |
| US5863790A (en) | 1997-05-14 | 1999-01-26 | Minnesota Mining And Manfacturing Company | Biological sterility indicator |
| US6828095B1 (en) * | 1997-05-29 | 2004-12-07 | Curis, Inc. | Modulators of morphogen expression and methods of identifying the same |
-
1998
- 1998-04-30 JP JP10120174A patent/JPH11313675A/ja active Pending
-
1999
- 1999-04-22 YU YU64900A patent/YU64900A/sh unknown
- 1999-04-22 KR KR1020007012054A patent/KR20010071193A/ko not_active Ceased
- 1999-04-22 EE EEP200000627A patent/EE200000627A/xx unknown
- 1999-04-22 AP APAP/P/2000/001982A patent/AP1329A/en active
- 1999-04-22 SK SK1608-2000A patent/SK16082000A3/sk unknown
- 1999-04-22 AU AU31634/99A patent/AU769124B2/en not_active Ceased
- 1999-04-22 PL PL99343817A patent/PL343817A1/xx not_active Application Discontinuation
- 1999-04-22 NZ NZ507625A patent/NZ507625A/en unknown
- 1999-04-22 TR TR2000/03182T patent/TR200003182T2/xx unknown
- 1999-04-22 UA UA2000116830A patent/UA72212C2/uk unknown
- 1999-04-22 IL IL13910099A patent/IL139100A0/xx unknown
- 1999-04-22 CA CA002326957A patent/CA2326957A1/en not_active Abandoned
- 1999-04-22 EA EA200001130A patent/EA004509B1/ru not_active IP Right Cessation
- 1999-04-22 GE GEAP19995635A patent/GEP20033056B/en unknown
- 1999-04-22 WO PCT/IB1999/000733 patent/WO1999057293A1/en not_active Ceased
- 1999-04-22 BR BR9910585-3A patent/BR9910585A/pt not_active IP Right Cessation
- 1999-04-22 CN CNB998079553A patent/CN1170941C/zh not_active Expired - Fee Related
- 1999-04-22 EP EP99913528A patent/EP1076713A1/en not_active Withdrawn
- 1999-04-22 US US09/674,311 patent/US6534268B1/en not_active Expired - Fee Related
- 1999-04-22 HU HU0102329A patent/HUP0102329A3/hu unknown
- 1999-04-22 HR HR20000736A patent/HRP20000736A2/hr not_active Application Discontinuation
- 1999-04-22 ID IDW20002196A patent/ID26704A/id unknown
-
2000
- 2000-10-24 BG BG104883A patent/BG64780B1/bg unknown
- 2000-10-27 ZA ZA200006080A patent/ZA200006080B/xx unknown
- 2000-10-27 NO NO20005433A patent/NO20005433D0/no not_active Application Discontinuation
-
2002
- 2002-10-03 US US10/263,788 patent/US20030040007A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU769124B2 (en) | 2004-01-15 |
| CA2326957A1 (en) | 1999-11-11 |
| EP1076713A1 (en) | 2001-02-21 |
| US20030040007A1 (en) | 2003-02-27 |
| NO20005433L (no) | 2000-10-27 |
| UA72212C2 (en) | 2005-02-15 |
| BR9910585A (pt) | 2001-01-09 |
| US6534268B1 (en) | 2003-03-18 |
| ZA200006080B (en) | 2001-10-29 |
| ID26704A (id) | 2001-02-01 |
| KR20010071193A (ko) | 2001-07-28 |
| EE200000627A (et) | 2002-02-15 |
| EA200001130A1 (ru) | 2001-04-23 |
| NZ507625A (en) | 2003-12-19 |
| CN1170941C (zh) | 2004-10-13 |
| JPH11313675A (ja) | 1999-11-16 |
| GEP20033056B (en) | 2003-08-25 |
| BG64780B1 (bg) | 2006-03-31 |
| HUP0102329A2 (hu) | 2001-10-28 |
| CN1307643A (zh) | 2001-08-08 |
| WO1999057293A1 (en) | 1999-11-11 |
| EA004509B1 (ru) | 2004-04-29 |
| IL139100A0 (en) | 2001-11-25 |
| YU64900A (sh) | 2003-10-31 |
| HUP0102329A3 (en) | 2006-03-28 |
| NO20005433D0 (no) | 2000-10-27 |
| PL343817A1 (en) | 2001-09-10 |
| HRP20000736A2 (en) | 2001-10-31 |
| AU3163499A (en) | 1999-11-23 |
| AP2000001982A0 (en) | 2000-12-31 |
| AP1329A (en) | 2004-11-22 |
| TR200003182T2 (tr) | 2001-02-21 |
| BG104883A (en) | 2001-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Villarreal et al. | Structure of human osteonectin based upon analysis of cDNA and genomic sequences | |
| US6534268B1 (en) | Human BMP-7 promoter and method for exploring bone-related substance by using the same | |
| Teufel et al. | Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes | |
| WO1996038590A9 (en) | Methods and compositions for identifying osteogenic agents | |
| EP1406916A2 (en) | Genes associated with mechanical stress, expression products therefrom, and uses thereof | |
| Taylor et al. | Identification of antisense transcripts of the chicken insulin-like growth factor-II gene | |
| US20040116671A1 (en) | Novel polypeptides and nucleic acids encoding same | |
| AU726918B2 (en) | TGFbeta signal transduction proteins, genes, and uses related thereto | |
| US6479259B1 (en) | Human peripheral nerve, tetrodotoxin-resistant sodium channel α-subunit polypeptide | |
| WO1997022697A9 (en) | TGFβ SIGNAL TRANSDUCTION PROTEINS, GENES, AND USES RELATED THERETO | |
| Shimuta et al. | Structure and expression of mitsugumin29 gene | |
| AU710551B2 (en) | Nucleic acid encoding a nervous tissue sodium channel | |
| US6475735B1 (en) | Human BMP-2 promoter and method for exploring bone-related substance by using the same | |
| CZ20004017A3 (cs) | Lidský BMP-7 promotor a způsob zjištění substancí ovlivňujících kost za použití tohoto promotoru | |
| MXPA00010413A (en) | Human bmp-7 promoter and method for exploring bone-related substance by using the same | |
| AU759569B2 (en) | Human BMP-4 promoter and method for exploring bone-related substance by using the same | |
| JPH104976A (ja) | Ｔａｂ１蛋白質及びそれをコードするｄｎａ | |
| CZ20004016A3 (cs) | Lidský BMP-4 promotor a způsob pro výzkum substancí ovlivňujících kosti za použití tohoto promotoru | |
| MXPA00010405A (en) | Human bmp-4 promoter and method for exploring bone-related substance by using the same |